PixarBio Announces Xi Chen, Dr. Amer Khalil, And Haining Dai Are Final Cofounders For All Public Filings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation announced the expansion of our founder’s team to be included in all public documents. Xi Chen, Haining Dai and Dr. Amer Khalil have been awarded cofounders status of PixarBio Corporation. Cofounders status is not awarded lightly but each scientist has demonstrated themselves to be entrepreneurial in mindset, and they have demonstrated great leadership as they have delivered on our mission every day since joining PixarBio Corporation.

“NeuroReleaseTM represents the holy-grail of pain treatment, and the quality of the KOL’s we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroReleaseTM “, said CEO Frank Reynolds.”

As Director of Analytical Chemistry, Xi Chen has led the commitment to exploring a wide range of formulations to treat severe neurological conditions such as Parkinson’s disease, acute/chronic pain, epilepsy, and spinal cord injury. Dr. Amer Khalil has worked for PixarBio CEO Frank Reynolds since 2010 at InVivo Therapeutics Corporation and now at PixarBio. Dr Amer Khalil, a Harvard trained Neurosurgeon, has been the lead Neurosurgeon on all FDA filings for PixarBio Corporation CEO Frank Reynolds since 2010. Dr. Khalil joined PixarBio as an investor and has not stopped adding value to our team. Last but not least is Haining Dai, PixarBio Director of preclinical neuroscience, who has co-invented with PixarBio CEO Frank Reynolds since 2007, and Haining was a co-inventor on the NeuroScaffold invented by PixarBio CEO Frank Reynolds. In 2011, Haining and Frank Reynolds shared the David F. Apple Award from the American Spinal Injury Association for being the first team to restore function in non-human primates after paralysis.

NeuroRelease^TM Platform, non-addictive, non-opiate pain platform
NeuroRelease^TM is a morphine strength platform, and non-addictive pain treatment for the hospital setting, for the battlefield, or for acute and chronic pain. First product FDA approval for the platform will be for a 14-day post-surgical pain treatment is expected in 2018. A major benefit of NeuroRelease^TM is there is no effect on locomotion nerve fibers, so patients can still control their locomotion nerve fibers movements and move around with a morphine strength treatment that is non-addictive. NeuroRelease^TM only effects sensory or pain signaling nerve fibers.

“Sprinkle-On” Version of NeuroRelease^TM
Like Vancomycin, an antibiotic that is sprinkled into incisions and wounds to reduce infection, NeuroRelease^TM can be sprinkled into incisions and wounds to provide pain treatment. We envision “Sprinkle On” NeuroRelease^TM, a 3-day sterile powder that can be used in a range of non-hospital settings such as the battlefield where the current use of morphine leads to immobilized soldiers. Since NeuroRelease^TM does not affect locomotion fibers, soldiers can move themselves to safety. Emergency room trauma is a logical application in the clinic and “Sprinkle On” NeuroRelease^TM will be a welcomed new pain treatment option for physicians performing surgery.

PixarBio NeuroRelease^TM pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments all have expected FDA approvals in 2020. NeuroRelease^TM is biodegradable, and it’s non-toxic so NeuroRelease^TM is the only non-opiate under review at the FDA that can be re-injected to extend treatment timelines. “NeuroRelease^TM represents the holy-grail of pain treatment, and the quality of the KOL’s we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroRelease^TM “, said CEO Frank Reynolds.

Last month PixarBio Corporation was awarded the Boston Business Journal’s “2016 Best Places to Work”. The award recognizes PixarBio as one of the region’s best firms, offering the greatest professional opportunities and work environments to innovate; the company is excited to bring “Sprinkle On” NeuroRelease^TM to market in 2019.

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione, Haining Dai, Xi Chen, and Dr Amer Khalil. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.